ALX-0171 is a therapeutic designed to combat Respiratory syncytial virus through inhalation. It is intended to be delivered directly to the lungs via nebulization, which is the site of Respiratory syncytial virus infection. Gontivimab (ALX-0171; VR-465) is a potent anti-Respiratory syncytial virus prefusion F protein mAb (llama-derived variable heavy-chain domain) with a KD value of 0.113 nM. It has demonstrated antiviral activity, with IC50s of 0.1 and 0.4 nM for Respiratory syncytial virus-A and Respiratory syncytial virus-B 18537 strain, respectively.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
VS-0424-XY229 | AbPlus™ Anti-RSV F Magnetic Beads (VS-0424-XY229) | IP, Protein Purification |
There are currently no Customer reviews or questions for VS-0923-FY252. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.